10th Annual New York Lung Cancer Symposium®

November 7, 2015
Crowne Plaza^® Times Square Manhattan
New York, NY

Overview

This annual meeting will provide an update on advances in the current management of lung cancer, as well as a focus on the future.
 
Participants will have an opportunity to learn from engaging presentations delivered by leading experts. Sessions will include emerging data, discussions on evolving standards of care, tumor board style case reviews and information that has the potential to impact their practice in the short term. 

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:

• Explain how to personalize treatment strategies for patients with advanced forms of lung cancer based on individual tumor characteristics
• Discuss current and emerging immunooncology strategies in the context of clinical trial findings and patient selection in advanced forms of lung cancer
• Describe current and emerging roles for agents that target the VEGF axis in advanced NSCLC
• Delineate best practices concerning the application of targeted therapies in frontline- and subsequent settings of advanced lung cancer
• Discuss evolving strategies to manage patients with acquired EGFR-TKI resistance in advanced NSCLC
• Detail current and emerging clinical roles for ALK inhibition in the management of advanced NSCLC
• Explain the current role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer
• Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Agenda Highlights

Workshop on Lung Cancer Immunotherapy in 2015

Key Data With Nivolumab (Anti PD-1) and Ipilimumab (Anti CTLA-4)

Current Status of Pembrolizumab (Anti PD-1) in Patients With Lung Cancer

Update on Clinical Trials of Atezolizumab (anti PD-L1) in Patients With Lung Cancer

Current Data and Ongoing Studies With Durvalumab (anti PD-L1) in Stage I-IV

How to Match the Right Agent to the Right Patient

How Might Immunotherapy Help Us Beat SCLC and Mesothelioma?

Targeting the VEGF Axis: Ligand and Receptor

New Applications for VEGF Antibodies

VEGF-Receptor Antibodies: The New Kid on the Block

Putting the Data into Practice: Challenging Cases in Lung Cancer

Challenging Cases

EGFR and ALK Inhibitors: Best Practices in 2015

Which EGFR TKI Do I Turn to First?

When Should I Change EGFR TKIs?

Third-Generation EGFR TKIs: How Have the Data Matured?

Applications of EGFR Antibodies in Frontline and TKI-Resistant Settings

An Update in the Landscape of ALK Inhibition

Putting the Data into Practice: Challenging Cases in Lung Cancer

More Challenging Cases

The Role of Chemotherapy in 2015

Cytotoxic Agents: When, and for How Long?

Click here to see the full agenda

Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY




Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY